Browsing Food Biosciences by Author "O'Callaghan, G. P."
48 Altered gut microbiota in stable patients with cystic fibrosis (CF) compared to controls and its relationship with intravenous (IV) antibiotic usage and lung functionBurke, D.G.; Fouhy, Fiona; Rea, Mary; Harrison, M.J.; STANTON, CATHERINE; O’Sullivan, Orla; Murphy, D. M.; O'Callaghan, G. P.; Eustace, J. A.; Shanahan, F.; et al. (Elsevier, 2015-06-05)Objective CF is associated with altered digestive function and thus nutrient availability for gut microbes in addition to altered gut microbiota, compared with healthy controls. Equally intensive antibiotic and nutritional therapy may further compound this. We present results from the largest CF gut microbiota study to date.
WS16.1 Clinical Outcomes of Real-World Kalydeco (CORK) study – Investigating the impact of CFTR potentiation on the intestinal microbiota, exocrine pancreatic function and intestinal inflammation prospectively over 12 monthsDeane, Jennifer; Ronan, N. J.; O'Callaghan, G. P.; Fouhy, Fiona; Rea, Mary; O'Sullivan, Orla; Hill, C. J.; Shanahan, F.; Ross, R Paul; McCarthy, M.; et al. (Elsevier, 2015-06-05)Objectives Ivacaftor is effective in the treatment of patients with CF and the G551D gating mutation. We present faecal analysis results of the CORK cohort, a single-centre, adult (n = 20), prospective, longitudinal study of G551D clinical responders (median follow-up 12 months), examining the gut microbiota, exocrine pancreatic function and intestinal inflammation on a 3 monthly basis after commencing treatment.